Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 6/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930115 | 0.80 | MMP13 (0.44) | MMP13ABCB1BCL2CTSKCTSS | |
| SCHEMBL9929780 | 0.73 | CTSK (0.39) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL9929801 | 0.71 | CTSK (0.39) | MMP13CTSKCTSSCTSLCTSB | |
| SCHEMBL9930114 | 0.70 | CTSS (0.36) | MMP13ABCB1BCL2CTSKCTSS | |
| SCHEMBL9929837 | 0.70 | CTSK (0.40) | MMP13CTSKCTSSCTSLCTSB | |
| SCHEMBL9940063 | 0.70 | CTSK (0.38) | CTSKCTSSCTSLCTSBCA2 | |
| SCHEMBL9929726 | 0.69 | CTSK (0.41) | MMP13CTSKCTSSCTSLCTSB | |
| SCHEMBL15083140 | 0.69 | PPARA (0.49) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL5033775 | 0.69 | PPARA (0.58) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL1093029 | 0.69 | PPARA (0.58) | CTSKCTSSCTSLCTSBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2019-01-01 | — | — | US | disclosed |
| EP-2288615-B1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-06-21 | — | — | EP | disclosed |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-04-27 | — | — | US | disclosed |
| US-9562069-B2 | Selective caspase inhibitors and uses thereof | NEW WORLD LABORATORIES INC. (CA) | 2017-02-07 | — | — | US | disclosed |
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2015-01-08 | — | — | US | disclosed |
| US-8791235-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2014-07-29 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| US-20110077190-A1 | Selective Caspase Inhibitors and Uses Thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2011-03-31 | — | — | US | disclosed |
| EP-2288615-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | New World Laboratories Inc. (CA) | 2011-03-02 | — | — | EP | disclosed |
| WO-2010133000-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009140765-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077190-A1 | Selective Caspase Inhibitors and Uses Thereof | CASP3, CASP1, HTRA2 | MMP13 127/4885ABCB1 1386/4885BCL2 27/4885 |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP3, CASP1, HTRA2 | MMP13 127/4885ABCB1 1386/4885BCL2 27/4885 |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, VIP, CASP5 | MMP13 122/4885ABCB1 1003/4885BCL2 53/4885 |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP5 | MMP13 100/4885ABCB1 1125/4885BCL2 24/4885 |
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | CASP1, CASP3, CASP5 | MMP13 100/4885ABCB1 1125/4885BCL2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.